(VIANEWS) – Shares of GENSIGHT BIOLOGICS (CAC 40: SIGHT.PA) dropped by a staggering 32.65% in 21 sessions from €3.4 to €2.29 at 13:59 EST on Thursday, after three successive sessions in a row of losses. CAC 40 is rising 1.11% to €6,962.11, following the last session’s downward trend.
About GENSIGHT BIOLOGICS
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, GENSIGHT BIOLOGICS has a trailing twelve months EPS of €-0.968.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GENSIGHT BIOLOGICS’s stock is considered to be overbought (>=80).
Volume
Today’s last reported volume for GENSIGHT BIOLOGICS is 44263 which is 75.59% below its average volume of 96138.
More news about GENSIGHT BIOLOGICS (SIGHT.PA).
